PharmaGraphX

Log in Get Started

Ondansetron

Zofran, Zofran ODT, Zuplenz

Antiemetic • 5-HT3 receptor antagonist

Premium

QT RiskSerotoninergic

Half-life

3-6 hours

Protein Binding

70-76%

Metabolized By

CYP3A4, CYP1A2, CYP2D6

External

Drugs.com

Boxed warning

QT prolongation — avoid in congenital long QT syndrome

Clinical alerts

Boxed warning

1 boxed warning

QT prolongation

Avoid combining with other QT-prolonging agents; check electrolytes

Serotonergic

Serotonin syndrome risk when combined with other serotonergic drugs

Mechanism of action

Selectively blocks serotonin 5-HT3 receptors in CTZ and vagal afferents

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Breast Cancer
·Allergy
·Nausea and Vomiting Chemotherapy-Induced
·Nausea Post Chemotherapy
·Postoperative Nausea and Vomiting

Interactions

1 curated · 0 major or contraindicated · select a row for management

Interacting drug	Severity	Effect
citalopram	moderate	Additive QT prolongation

Common adverse effects

Headache
Constipation
Dizziness
Fatigue

Food, alcohol & herbal

Alcohol · minor

No significant interaction

Pharmacokinetics

Half-life: 3-6 hours
Protein binding: 70-76%
Metabolised by: CYP3A4, CYP1A2, CYP2D6

Pregnancy & lactation

Not recorded for Ondansetron. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database, curated interaction pairs.

Not a substitute for clinical judgement

Ondansetron

Zofran, Zofran ODT, Zuplenz

Antiemetic • 5-HT3 receptor antagonist

Premium

QT RiskSerotoninergic

Half-life

3-6 hours

Protein Binding

70-76%

Metabolized By

CYP3A4, CYP1A2, CYP2D6

External

Drugs.com

Boxed warning

QT prolongation — avoid in congenital long QT syndrome

Clinical alerts

Boxed warning

1 boxed warning

QT prolongation

Avoid combining with other QT-prolonging agents; check electrolytes

Serotonergic

Serotonin syndrome risk when combined with other serotonergic drugs

Mechanism of action

Selectively blocks serotonin 5-HT3 receptors in CTZ and vagal afferents

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Breast Cancer
·Allergy
·Nausea and Vomiting Chemotherapy-Induced
·Nausea Post Chemotherapy
·Postoperative Nausea and Vomiting

Interactions

1 curated · 0 major or contraindicated · select a row for management

Interacting drug	Severity	Effect
citalopram	moderate	Additive QT prolongation

Common adverse effects

Headache
Constipation
Dizziness
Fatigue

Food, alcohol & herbal

Alcohol · minor

No significant interaction

Pharmacokinetics

Half-life: 3-6 hours
Protein binding: 70-76%
Metabolised by: CYP3A4, CYP1A2, CYP2D6

Pregnancy & lactation

Not recorded for Ondansetron. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database, curated interaction pairs.

Not a substitute for clinical judgement